AI주식인사이트AI Stock Insight
B

휴메딕스

200670KOSDAQ

63.0 / 100

Reference Date: 2026-10-23

Financial Score36.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Declined 5.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HumeDx operates in two main business segments: the Aesthetic Division, producing fillers, botulinum toxin, cosmetics, and medical devices, and the CMO Division, specializing in specialty pharmaceuticals, osteoarthritis treatments, and raw material production. The company leverages its proprietary HI (High molecular Ideal reticulated matrix) technology to develop long-lasting fillers and high-performance cosmetics using pharmaceutical-grade HA and PDRN.

Number of Employees

377people

Average Salary

56.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
5.03Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR
0.87Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
19.61Industry Average 8.007.0Point

2.5x industry avg (excellent)

Debt Ratio
1.15Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲5.7% (2-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲6.9% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 17.6% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 23,600Won52-week high 51,50052-week low 22,600
1-month return2.0Point

1m -5.79% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral기업설명회(IR)개최2026-10-21